Imara Inc


Imara Inc

  • Price (USD)14.04
  • Today's Change-0.01 / -0.07%
  • Shares traded85.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jan 22 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated--
  • Employees16.00
  • Location
    Imara Inc116 HUNTINGTON AVENUE, 6TH FLOORBOSTON 02116United StatesUSA
  • Phone+1 (617) 206-2020
  • Fax+1 (302) 655-5049
  • Websitehttps://imaratx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Evofem Biosciences Inc278.00k-114.43m230.02m53.00--5.72--827.42-1.93-1.930.00470.49470.0037--0.28435,245.28-151.24-239.25-323.65-402.0821.94---41,161.15--1.51-2.460.5444------36.37--55.43--
Neubase Therapeutics Inc0.00-17.38m233.63m3.00--7.46-----0.9026-0.90260.001.350.00-------74.01-87.20-84.14-100.52-----------63.090.0044------33.47--31.12--
Otonomy Inc313.00k-45.01m237.76m49.00--3.16--759.62-1.33-1.330.00881.560.003----6,387.76-43.42-47.27-48.48-50.70-184.35---14,379.87-10,950.49---45.230.1678---19.46--11.30---2.19--
Sol Gel Technologies Ltd10.73m-29.40m240.82m61.00--4.21--22.44-1.37-1.370.49892.490.1599--3.08175,967.20-43.81---49.42-------273.91------0.00--17,655.04--23.58------
AVEO Pharmaceuticals, Inc.5.90m-28.54m241.71m19.00--5.38--40.99-1.54-1.540.31311.560.0888--5.51310,368.40-42.99-49.79-59.92-99.99-----483.99-162.43----0.2529--432.359.70276.17------
Chiasma Inc142.00k-67.02m242.78m48.00--2.20--1,709.70-1.45-1.450.0031.910.0009--1.592,958.33-44.46-42.03-48.95-48.2197.89---47,195.77--8.95-21.680.00-------16.18------
Clever Leaves Holdings Inc0.00-847.40k242.99m4.00--1.20-----0.2282-0.22820.008.160.00----0.000.0951--0.0954--------------0.00-------1,828.87------
Imara Inc-100.00bn-100.00bn244.40m16.00--2.58----------5.45----------------------------0.00-------106.96------
Checkpoint Therapeutics Inc1.07m-21.68m245.74m8.00--6.78--230.31-0.4533-0.45330.02130.53360.0376--6.93133,375.00-76.45---102.05-------2,032.05------0.00---51.28--32.04------
Palatin Technologies, Inc.-267.95k-21.87m245.99m20.00--3.20-----0.0929-0.0929-0.00110.3349-0.0027-----13,397.50-21.96-10.23-23.69-15.34-------15.967.43--0.00---99.80-60.92-162.69------
Metacrine Inc-100.00bn-100.00bn248.14m35.00--2.52----------3.79----------------------------0.0866---100.00---12.05------
Aptinyx Inc2.48m-52.34m253.03m43.00--1.72--101.90-1.26-1.260.05842.330.0212--6.9257,744.19-44.64---46.91-------2,108.06------0.00---44.19---7.75------
9 Meters Biopharma Inc0.00-65.44m253.32m8.00--51.64-----0.9605-0.96050.000.02420.00----0.00-551.76-306.57-26,912.24---------521.25---44.360.2589-------11.95------
CTI BioPharma Corp0.00-45.64m254.34m25.00--5.31-----0.6791-0.67910.000.63510.00----0.00-75.01-67.27-107.38-106.96-------221.29---52.110.1078---87.28-43.88-36.12------
OncoSec Medical Inc0.00-45.72m255.98m42.00--12.34-----1.71-1.710.000.58610.00----0.00-159.94-113.86-236.24-137.28-----------513.740.0734-------39.56------
Data as of Jan 22 2021. Currency figures normalised to Imara Inc's reporting currency: US Dollar USD

Institutional shareholders

40.32%Per cent of shares held by top holders
HolderShares% Held
OrbiMed Advisors LLCas of 30 Sep 20202.72m15.63%
Fidelity Management & Research Co. LLCas of 30 Sep 20202.48m14.23%
Deerfield Management Company LPas of 30 Sep 2020517.65k2.97%
Rock Springs Capital Management LPas of 30 Sep 2020358.94k2.06%
BlackRock Fund Advisorsas of 30 Sep 2020306.87k1.76%
RA Capital Management LPas of 30 Sep 2020249.74k1.44%
The Vanguard Group, Inc.as of 30 Sep 2020180.54k1.04%
Geode Capital Management LLCas of 30 Sep 202082.92k0.48%
SSgA Funds Management, Inc.as of 30 Sep 202064.01k0.37%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202061.08k0.35%
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.